Efficacy of the H7N9 vaccine as a candidate for the Korean avian influenza antigen bank
Year: 2024
Type: article
Abstract: The avian influenza A virus (H7N9), first detected in China in 2013, is a zoonotic virus that remains persistent in bird populations despite a decline in human cases owing to control measures. Therefore, this study aimed to develop a vaccine as one preventive strategy in anticipation of the potential entry of H7N9 into Korea. Using the hemagglutinin and neuraminidase consensus sequences of H7N9 from 2018–2019, a recombinant H7N9 vaccine, rgAPQAH7N9, was developed, and its protective efficacy in specific pathogen-free chickens was evaluated. The rgAPQAH7N9 vaccine exhibited proliferation in eggs and demonstrated high immunogenicity, with a hemagglutination inhibition titer of 9.3 log 2 . Furthermore, the vaccine provided complete protection, as vaccinated chickens did not exhibit clinical signs or viral shedding. Moreover, when the rgAPQAH7N9 vaccine was boosted, the resulting immunity was long-lasting, with hemagglutination inhibition titers > 7 log2 persisting after 6 months. Therefore, the rgAPQAH7N9 vaccine virus may be considered a potential candidate for inclusion in the avian influenza antigen bank to ensure preparedness for emergency vaccination in poultry. • A recombinant H7N9 vaccine (rgAPQAH7N9) was established. • The rgAPQAH7N9 vaccine demonstrated robust immunogenicity in SPF chickens. • rgAPQAH7N9 induced complete protection, preventing clinical signs & viral shedding. • Boosting the rgAPQAH7N9 vaccine yielded long-lasting immunity.
Authors: Hyerim Do, Mingeun Sagong, Yoon kyoung Lee, Hyun-Kyu Cho, Youn-Jeong Lee, Seong-Hee Kim
Institution: Animal and Plant Quarantine Agency
Language: English
Subfield: Epidemiology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $3,160
Award: G6336045330
OpenAlex ID: W4403695197